Selexipag
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 356 publications
Real-World Experience of Midodrine in Hospital Setting in Pulmonary Arterial Hypertension.
Journal: CHEST pulmonary
Published: September 03, 2026
Corrigendum to: Beghetti M, Nygaard Axelsen L, Borissoff, JI, et al. A Prospective, Multicenter, Open-Label, Single-Arm Phase 2 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Selexipag in Children With Pulmonary Arterial Hypertension. CHEST. 2026;169(5):1330-1344.
Journal: Chest
Published: August 10, 2026
Implementation and use of risk minimization control tools in the EU: A multistakeholder survey.
Journal: British journal of clinical pharmacology
Published: June 22, 2026
Aging-driven transcriptional programs in diabetic kidney disease: multi-omics discovery of diagnostic biomarkers and drug-repurposing targets.
Journal: Clinical epigenetics
Published: June 17, 2026
Pharmacovigilance assessment of gout: a real-world study using the FAERS database.
Journal: Frontiers in pharmacology
Published: April 29, 2026
Towards an integrated and proactive management of pulmonary hypertension in systemic sclerosis: a practical approach for early diagnosis and optimal patient management.
Journal: Rheumatology advances in practice
Published: April 14, 2026
A Rare Case of Multi-System Involvement and Hereditary Pulmonary Hypertension Caused by De Novo Heterozygous CAV1 Mutation in a Pediatric Patient.
Journal: Children (Basel, Switzerland)
Published: April 13, 2026
Selexipag for Pulmonary Hypertension, TAVI and more.
Journal: Anatolian journal of cardiology
Published: April 01, 2026
Efficacy of short-term, low-dose pulmonary vasodilators for chronic thromboembolic pulmonary hypertension: a retrospective pilot study.
Journal: Respiratory investigation
Published: March 26, 2026
Selexipag in systemic sclerosis-associated pulmonary arterial hypertension: long-term real-world data from a multicentre Italian cohort.
Journal: Rheumatology (Oxford, England)
Published: March 21, 2026
Editorial Comment: "Could We Maintain the Initial Efficacy of Triple Sequential Combination Therapies with Selexipag Against Progressive Deterioration Risk in Patients with Pulmonary Arterial Hypertension: Insights from a Single-Centre Study".
Journal: Anatolian journal of cardiology
Published: March 17, 2026
Last Updated: 09/26/2026